Are you Alexandros Anyfantakis?

Claim your profile

Publications (3)

  • ND Pilatis · A Anyfantakis · P Iakovis · [...] · DV Cokkinos
    Conference Paper · Feb 2006
  • [Show abstract] [Hide abstract] ABSTRACT: Encouraging results with the use of the sirolimus-eluting stent (SES) have been recently presented in several multi-center trials. In the present study, the short- and mid-term clinical outcomes of the SES in everyday clinical practice of interventional cardiology were compared with a strategy using conventional bare metal stents. In a total of 530 consecutive patients (males 86%, mean age 61 +/- 10 years) who had been treated with a SES were compared with a control group of 398 patients (males 87%, mean age 59 +/- 11 years) treated with a bare metal stent before the use of SES. In-hospital results and clinical outcomes during follow-up (11.22 +/- 3.4 versus 11.41 +/- 3.1 months) were obtained. Patients treated with SES had more risk factors for coronary artery disease or multivessel disease compared to those with treated bare metal stent. The clinical success rate was 99.6% in the SES group and 98.5% in the bare metal stent group (p = ns), and non-Q-wave myocardial infarction (MI) occurred in 5.7% and 4.0% of patients, respectively. The incidence of death or MI during follow-up was not different (1.1% versus 1.3% and 0.8% versus 1.8%; p = ns). Percutaneous or surgical revascularization for target lesion restenosis was required in 2.1% of patients treated with SES and in 10.1% of those with bare metal stents (p < 0.001), and the event-free survival from death, cerebrovascular accident, MI or any percutaneous or surgical revascularization was 93.13% and 83.63%, respectively (p < 0.01). The implantation of the SES is associated with excellent in-hospital and mid-term results, mainly because of dramatic reductions in the need for repeat revascularization, despite a higher risk factor profile and more complex lesion characteristics.
    Article · Sep 2005 · The Journal of invasive cardiology
  • Constantinos J Limas · Panayotis Iakovis · Alexandros Anyfantakis · [...] · Dennis V Cokkinos
    [Show abstract] [Hide abstract] ABSTRACT: In this study, we examined the hypothesis that dilated cardiomyopathy (DCM) shares genetic risk factors with other diseases of presumed autoimmune etiology, and, therefore, the same multiple genes in combination with environmental factors lead to numerous different autoimmune diseases. In accordance with this hypothesis, we showed an increased prevalence of autoimmune diseases in first-degree relatives of patients with DCM. Also, T-cell activation, as reflected in high levels of the soluble interleukin-2 receptor, appears to identify patients with DCM with a clustering of autoimmune diseases.
    Article · Jun 2004 · The American Journal of Cardiology